APVO News and Press, Aptevo Therapeutics Inc. From 07/21/19

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

Expands Options for Patients with Potential for  Reduced Reconstitution Time and Infusion Volume SEATTLE, June 25, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeuti...

Aptevo Therapeutics (NASDAQ: APVO ): Q1 GAAP EPS of -$0.44 in-line. More news on: Aptevo Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Achieves 73% Increase in First Quarter 2019 Year-Over-Year IXINITY® Net Revenue On Target for Launch of New 3,000 IU IXINITY Assay Mid-2019 Advances Enrollment in APVO436 and APVO210 Phase 1 Clinical Studies; Anticipates Top-Line Preliminary Data Read-outs in the Third a...

Reports 73% Increase in IXINITY Year-Over-Year Quarterly Net Revenue in Q1 2019 Anticipates Launching New IXINITY 3,000 IU Assay Mid-2019 Advances Dosing in Additional Cohorts in APVO436 and APVO210 Clinical Programs On Schedule to File a CTA for ALG.APV-527 in Q4 2019 SEAT...

The following slide deck was published by Aptevo Therapeutics Inc. in conjunction with this Read more ...

APVO436 Preclinical Data Continue to Show Promising Results Supporting Clinical Development for the Treatment of Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS) and Differentiation from a Competitor Candidate Phase 1/1b Clinical Study of APVO436 Continuing D...

SEATTLE, March 25, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that preclinical data for two of its ADAPTIR™ bispecific antibody candidates will...

Aptevo Therapeutics (NASDAQ: APVO ) has commenced dosing in a Phase 1 clinical trial of APVO210, a novel bispecific antibody candidate built on ADAPTIR therapeutic protein platform developed to treat autoimmune and inflammatory diseases. More news on: Aptevo Therapeutics Inc., Healthcare...

Unique Mechanism of Action Suppresses Inflammation and Immune Activation  Without Promoting Pro-Inflammatory Lymphocyte Stimulation Preliminary Phase 1 Data Read-outs Anticipated Q3 and Q4 2019 SEATTLE, March 20, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO)...